ReviewThe Journal of surgical research2014
The prognostic value of liver tumor T cell infiltrates.
Review in The Journal of surgical research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Prognostic value of tumor-infiltrating lymphocytes in hepatocellular carcinoma: A meta-analysis.Medicine · 2018Pooled it
- Breaking down physical barriers: strategies to improve lymphocyte infiltration for effective neoantigen-based therapies.Frontiers in immunology · 2025Review
- Role of stromal PD-L1 expression in colorectal liver metastasis.BMC cancer · 2024Article
- Integrated Single-cell and Transcriptome Sequencing Analyses Identified PREX1 as an Immune-related Prognostic Biomarker for Liver Hepatocellular Carcinoma.International journal of medical sciences · 2024Article
- CD4Journal of translational medicine · 2023Article
- Gene Alterations, Mediators, and Artificial Intelligence in Colorectal Liver Metastases.Cells · 2022Article
- Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma.Bioscience reports · 2022Review
- Article
- PLCε1 suppresses tumor growth by regulating murine T cell mobilization.Clinical and experimental immunology · 2020Article
- Multifaceted Role of the Placental Growth Factor (PlGF) in the Antitumor Immune Response and Cancer Progression.International journal of molecular sciences · 2019Review
- Prolonged tumor response associated with sequential immune checkpoint inhibitor combination treatment and regorafenib in a patient with advanced pretreated hepatocellular carcinoma.Journal of gastrointestinal oncology · 2019Article
- Metastasectomy for Tumor-Infiltrating Lymphocytes: An Emerging Operative Indication in Surgical Oncology.Annals of surgical oncology · 2018Article
- Immunotherapy for hepatocellular carcinoma patients: is it ready for prime time?Cancer immunology, immunotherapy : CII · 2018Review
- Tumor reductive therapies and antitumor immunity.Oncotarget · 2017Review
- Immunosuppression in liver tumors: opening the portal to effective immunotherapy.Cancer gene therapy · 2017Review
- Tumor-associated immune factors are associated with recurrence and metastasis in non-small cell lung cancer.Cancer gene therapy · 2017Article
- Tumor-associated GM-CSF overexpression induces immunoinhibitory molecules via STAT3 in myeloid-suppressor cells infiltrating liver metastases.Cancer gene therapy · 2016Article
- Tumor-infiltrating T lymphocytes improve clinical outcome of therapy-resistant neuroblastoma.Oncoimmunology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Tumor infiltrating lymphocytes (TIL) have been demonstrated to predict oncologic outcomes following resection of primary intrahepatic neoplasms and metastatic liver tumors. Despite strong immunosuppressive factors within the intrahepatic space, TIL are frequently demonstrated in liver tumors. The presence of TIL within liver tumors provides evidence of a host immune response that may be protective, but often is rendered ineffective by tumor induced immune dysfunction. In this review, we discuss techniques involved in studying TIL and subsets of TIL commonly identified. We emphasize the unique nature of the intrahepatic milieu that promotes immunosuppression, and how liver TIL and TIL ratios can be used as indicators of prognosis. Several types of primary and metastatic liver tumors are considered to highlight the similarities and important differences in TIL responses, which likely reflect how intrahepatic immunity is influenced by tumor biology. The studies we discuss indicate that tumor infiltration by suppressor cells and expression of immunoinhibitory molecules by TIL limits the anti-tumor immune function of effector T cells. Most patients fail to mount an adequate immune response to liver tumors, which provides compelling rationale for clinical study of immunotherapy for intrahepatic neoplasms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.